Jasper Therapeutics, Inc. (JSPR) stock
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$10.34−1.43 (-12.15%)
Close on Nov 17, 2026Market cap $344.06MP/E –Yield –
Earnings
Jasper Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 9, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.10
-$1.74 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Jasper Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 14, 2026after the close | – | – | -$0.10 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | – | – | -$0.04 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025after the close | – | – | -$1.74 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | – | – | -$1.41 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | – | – | -$1.62 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | – | – | -$1.24 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 4, 2024before the open | – | – | -$1.50 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 11, 2023after the close | – | – | -$0.15 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 12, 2023after the close | – | – | -$0.16 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023after the close | – | – | -$0.36 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | – | – | -$0.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 12, 2022after the close | – | – | -$0.29 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022after the close | – | – | -$0.06 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 18, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021after the close | – | – | -$0.69 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Jasper Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Jasper Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Jasper Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- News
- News
- Results
- Update
- Update
- Update
- Results
- Results
- News
- News
- News
- News
See a number that looks wrong?